Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis
- 270 Downloads
Previously, the combination of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and bevacizumab (BEV) was investigated. A subgroup analysis of the IMpower150 trial, which investigated the combination of atezolizumab, carboplatin, paclitaxel, and bevacizumab (ABCP), demonstrated the benefit of ABCP in patients harboring EGFR mutations. This study aims to assess the prognostic significance of the qualification for BEV use and the proportion of patients who potentially benefit from BEV-containing combination therapy before and after initial EGFR-TKI treatment.
We retrospectively analyzed the data of 297 patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) harboring EGFR mutations who had received EGFR-TKIs. We performed statistical analyses using the Kaplan–Meier method and the Cox regression adjusted for risk factors.
Of the 297 patients, 203 (68%) were eligible to receive BEV (“BEV fit”) at the time of EGFR-TKI initiation. Among the “BEV unfit” patients at baseline (n = 70), 14 (20%) became eligible to receive ABCP (“ABCP fit”) at the time of EGFR-TKI failure. The median overall survival (OS) of the “BEV fit” and “BEV unfit” patients was 26.2 [95% confidence interval (CI) 23.7–31.2] and 19.1 (95% CI 15.0–25.1) months, respectively (P < 0.001). The multivariate analysis revealed a marked correlation between survival and the qualification for BEV use.
The qualification for BEV use at baseline is independently related to the OS. Some patients harboring EGFR mutations, including those who were “BEV unfit” at baseline, could be eligible for the ABCP regimen after EGFR-TKI treatment.
KeywordsNon-small cell lung cancer Epidermal growth factor Tyrosine kinase inhibitor Bevacizumab Prognosis
Non-small cell lung cancer
Epidermal growth factor receptor
Tyrosine kinase inhibitor
Vascular endothelial growth factor
American Society of Clinical Oncology
Erlotinib and bevacizumab
Immune checkpoint inhibitor
Atezolizumab plus carboplatin, paclitaxel, and bevacizumab
Anaplastic lymphoma kinase
Eastern Cooperative Oncology Group-Performance Status
Not other specified
We thank Enago (https://www.enago.jp/) for the English language review.
TH, YO, and KH acquired the clinical data. TH and YO drafted the manuscript. TH, YO, KH, and YH interpreted the data.
This study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
Conflict of interest
This study protocol was approved by the Ethics Committee of the Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital and was conducted in accordance with the tenets of the Declaration of Helsinki.
- Gridelli C et al (2016) BEVERLY: rationale and design of a randomized open-label phase III trial comparing bevacizumab plus erlotinib versus erlotinib alone as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small-cell lung cancer. Clin Lung Cancer 17(5):461–465CrossRefPubMedGoogle Scholar
- Hattori Y et al (2015) A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109). Lung Cancer 87(2):136–140CrossRefPubMedGoogle Scholar
- Herbst RS et al (2011) Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 377(9780):1846–1854CrossRefPubMedPubMedCentralGoogle Scholar
- Hiranuma O et al (2019) Rationale and design of a phase II trial of osimertinib combined with bevacizumab in patients with untreated epidermal growth factor receptor-mutated non-small-cell lung cancer and malignant pleural and/or pericardial effusion (spiral II study). Clin Lung Cancer 20(3):e402–e406CrossRefPubMedGoogle Scholar
- Mok TS et al (2017) Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376(7):629–640Google Scholar
- Nakagawa K et al (2019) RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 37(15_suppl):9000Google Scholar
- Zhou C et al (2015) BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol 33(19):2197–2204CrossRefPubMedGoogle Scholar
- Zinner RG et al (2015) PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol 10(1):134–142CrossRefPubMedGoogle Scholar